The Pathophysiology of Hereditary Angioedema by Bruce L Zuraw
SYMPOSIUM REPORT SUPPLEMENT
The Pathophysiology of Hereditary Angioedema
Bruce L. Zuraw, MD
Abstract: Hereditary angioedema (HAE) causes recurrent episodes
of angioedema that may be very severe and are frequently associated
with significant morbidity and even mortality. Understanding the
pathophysiology of this disease is crucial for proper diagnosis and
management of these patients. HAE is caused by mutations in the
SERPING1 gene that result in decreased plasma levels of functional
C1 inhibitor. A large number of different mutations have been
described that result in HAE. About 15% of patients have a mutation
at or near the active site of the reactive mobile loop, resulting in a
protein that lacks functional activity (type II HAE). Type I HAE is
caused by a diverse range of mutations, some of which cause the
nascent protein to misfold and thus to be unable to enter the
secretory pathway. The primary mediator of swelling in HAE is
bradykinin, a product of the plasma contact system. Bradykinin
induces increased vascular permeability by activating the bradykinin
B2 receptor, which results in phosphorylation of vascular endothe-
lial cadherin. The regulation of both the bradykinin B2 receptor and
peptidases that degrade bradykinin may influence HAE disease
severity. HAE results from mutations in the SERPING1 gene that
lead to a loss of functional C1 inhibitor. Attacks of angioedema
result from generation of bradykinin, which acts on bradykinin B2
receptors to enhance vascular permeability.
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In 1888, William Osler described a familial form of angio-edema associated with significant morbidity and mortality.1
He called this disease hereditary angio-neurotic edema
(HANE), a name that has subsequently been shortened to
hereditary angioedema (HAE). The prevalence of HAE is not
known for certain, but has been estimated to range from
1:30,000 to 1:80,000 in the general population without any
known sex, ethnic, or racial differences.2
HAE is clinically characterized by recurrent episodes of
angioedema that typically involve the extremities, gastroin-
testinal tract, face, oropharynx, larynx, or external genitalia.
Patients with HAE experience discrete episodes of nonpru-
ritic nonpitting angioedema at these sites.2,3 HAE attacks are
classically distinguished from allergic or idiopathic angio-
edema by their longer duration (typically 72–96 hours),
absence of accompanying urticaria and failure to respond to
antihistamines or corticosteroid therapy.
Most often, patients with HAE become symptomatic
during childhood. Fifty percent of HAE patients first experi-
ence a swelling episode before age 10, with some patients
manifesting angioedema as early as 1 year of age.4,5 Most
patients then experience a worsening of symptoms around
puberty.3 Occasionally, patients with HAE do not begin to
show evidence of angioedema until their late teens or early
adulthood. Rare patients with HAE have been reported who
never experience angioedema, but are identified through
screening family members of a symptomatic patient.5,6 Al-
though some patients seem to experience decreased symp-
toms as they age, other patients continue to experience HAE
attacks throughout their lives.
This article will address 4 questions that will help
illuminate the clinical issues described above: 1) What is the
underlying basis of HAE? 2) Why do patients become C1
inhibitor deficient? 3) What is the primary mediator of swell-
ing in HAE? and 4) What is the molecular basis of bradyki-
nin-induced swelling?
WHAT IS THE UNDERLYING BASIS OF HAE?
The pathophysiologic basis of HAE as a deficiency of
a plasma inhibitor was discovered in the early 1960s. Land-
erman et al reported that patients with HAE lacked an
inhibitor of serum globulin permeability factor (shown sub-
sequently to be activated Hageman factor) or plasma kal-
likrein.7 The next year, Donaldson and Evans, in a seminal
publication, identified the missing inhibitor as C1 inhibitor.8
The identification of C1 inhibitor deficiency as the basis of
HAE allowed the pathophysiologic and molecular mecha-
nisms of HAE to be explored.
C1 inhibitor is a broad-spectrum serine protease inhib-
itor that is a member of the serpin (serine protease inhibitor)
superfamily, with significant homology to 1-antitrypsin. It is
the major inhibitor of several complement proteases (C1r,
C1s, MASP-1, and MASP-2) and contact system proteases
(plasma kallikrein and activated Hageman factor [coagulation
factors XIIa and XIIf]).9 C1 inhibitor is also an inhibitor of
the fibrinolytic protease plasmin and the coagulation protease
factor XIa.
Like other serpins, C1 inhibitor functions as a “molec-
ular mousetrap,” undergoing large scale rearrangement and
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trapping the target protease when it is cleaved.10 C1 inhibitor
is a suicide inhibitor, forming a 1:1 stoichiometric complex
with the target protease, which is followed by clearance of the
entire complex. In cases of overwhelming proteolytic activa-
tion, C1 inhibitor can be cleaved into a modified inactive
form without forming a complex with or inhibiting the
protease.11
The 2.1-kb C1 inhibitor cDNA was initially cloned and
sequenced in 1986.12 C1 inhibitor is a 110-kD single-chain
glycoprotein consisting of 478 amino acids plus a 22-residue
signal peptide.12 The protein is organized into 2 domains: the
N-terminal 100 amino acids contain the N- and O-linked
carbohydrates, and the C-terminal 378 amino acids contain
the active site in a stressed loop conformation typical of the
serpins.12 The 17,159-basepair genomic sequence of the gene
was published in 1991.13 The gene, now named SERPING1,
is located on chromosome 11 (p11.2-q13), contains 8 exons
and 7 introns, does not contain a 5 TATA box, and is
distinguished by 17 Alu repeats in introns 3 to 7. More
recently, the crystal structure has been solved.14
The C1 inhibitor deficiency in HAE has been shown to
result from mutations of the SERPING1 gene. A large num-
ber of SERPING1 mutations have been identified,9,15–18 with
additional mutations still being reported. A database tabulat-
ing known SERPING1 gene mutations (http://hae.enzim.hu)
currently lists more than 150 different mutations identified in
patients with HAE.
The autosomal dominant pattern of HAE was recog-
nized by Osler in 1888.1 Each child of an affected patient has
a 50% chance of having HAE. Importantly, HAE does not
skip generations. Lack of a positive family history of angio-
edema cannot, however, be used to exclude the diagnosis.
Although 75% of patients give a history of having an
affected parent, the remaining 25% of patients presumably
have a de novo mutation of the C1 inhibitor gene that results
in HAE.19
WHY DO PATIENTS BECOME C1
INHIBITOR DEFICIENT?
Two different forms of HAE associated with low C1
inhibitor function have been identified.20 Type I HAE is the
most common form, accounting for about 85% of cases. It is
associated with decreased antigenic levels of C1 inhibitor in
the plasma. A large number of different SERPING1 muta-
tions have been associated with type I HAE, including mis-
sense, nonsense, frameshift, deletion, and insertion muta-
tions. In general, type I HAE is caused by mutations in the C1
inhibitor gene that result in either truncated proteins or
misfolded proteins that cannot be secreted.21
This failure of some type I C1 inhibitor mutant proteins
to be efficiently secreted is presumably because of a failure of
the mutant protein to correctly fold into the native C1 inhib-
itor structure. Newly synthesized proteins are cotranslation-
ally translocated from the ribosome into the endoplasmic
reticulum (ER), where they must fold into a native confor-
mation before they are able to exit to the Golgi apparatus.
Protein folding has been shown to follow a thermodynamic
gradient in which the most stable or native conformation lies
at a free energy minimum,22 and specialized ER proteins
(chaperones and folding enzymes) interact with the nascent
protein, helping it to fold correctly and avoid kinetic traps
until it reaches native conformation. If the protein fails to
reach this conformation, it is no longer targeted for secretion;
instead, it is retrotranslocated back into the cytosol for deg-
radation in the proteasome.23
Approximately another 15% of HAE patients have
type II HAE. This type of HAE is characterized by normal
plasma antigenic levels of C1 inhibitor but decreased
functional levels of the plasma C1 inhibitor.20,24 Most of
SERPING1 mutations associated with type II HAE involve
residues at or near the active site on the reactive mobile
loop that result in a mutant C1 inhibitor protein that is
secreted but is dysfunctional.25
In both type I and type II HAE, the low functional level
of C1 inhibitor results in diminished regulation of the com-
plement and contact systems. Because C1 inhibitor functions
as a suicide inactivator, every molecule of C1r, C1s, plasma
kallikrein, or factor XIIa that is inhibited consumes a mole-
cule of C1 inhibitor. Because of the reduced function of C1
inhibitor in HAE, turnover of the C1 inhibitor may be higher
in patients with HAE.26 Clearance of radiolabeled C1 inhib-
itor appears to support this hypothesis,27 although pharmaco-
kinetic analyses of infused C1 inhibitor concentrates have not
confirmed the evidence of more rapid turnover of C1 inhibitor
in HAE patients. This is an area that will require more
information.
WHAT IS THE PRIMARY MEDIATOR OF
SWELLING IN HAE?
Identification of the mediator of swelling in patients
with HAE has important implications for developing more
effective treatments for the disease. Incubation of plasma
from HAE patients ex vivo at 37°C generates a factor that
causes smooth muscle contraction and increased vascular
permeability.28 It was quickly recognized that this vascular
permeability enhancing factor was likely to be the mediator
of swelling in HAE; however, the identity of this factor was
an area of significant controversy for many years. C1 inhib-
itor is a major inhibitor of several complement proteases and
contact system proteases. During HAE attacks, each of these
plasma proteolytic cascades is activated and several vasoac-
tive substances are potentially generated. From these consid-
erations, 2 potential mediators of swelling in HAE were
identified: C2 kinin, generated through activation of the
classic complement pathway,29 and bradykinin, generated
through activation of the contact system.30
Over time, compelling laboratory and clinical data have
demonstrated that bradykinin is the primary mediator that
enhances vascular permeability in HAE.11,30–39 Bradykinin is
a nanopeptide generated by activation of the contact system.
In this system, active plasma kallikrein cleaves high-molec-
ular-weight kininogen to release bradykinin. The generated
bradykinin can potently increase vascular permeability by
binding to its cognate receptor (the B2 bradykinin receptor)
on vascular endothelial cells. Active plasma kallikrein has
been detected in the blister fluid of HAE patients but not in
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that of normal controls.30 Incubation of HAE plasma ex vivo
was shown to generate bradykinin.31,32 Furthermore, the con-
tact system is activated in vivo during attacks of angioedema
in HAE patients,33–35 and increased levels of bradykinin have
been measured in plasma during attacks of angioedema.36
Contact system activation was also shown to cleave C1
inhibitor into a nonfunctional form,11 and the plasma level of
cleaved nonfunctional C1 inhibitor is increased during attacks
of angioedema in HAE patients.37 Importantly, the activity to
enhance vascular permeability that is generated by ex vivo
incubation of C1 inhibitor-deficient plasma was shown to be
independent of C2 but completely dependent on high-molec-
ular-weight kininogen (the substrate for bradykinin).38 C1
inhibitor knockout mice show a persistent increase in vascu-
lar permeability, which can be corrected by administration of
exogenous C1 inhibitor.39 Additionally, the vascular perme-
ability defect depends on both plasma kallikrein activity and
bradykinin receptor signaling.39 In view of the overwhelming
evidence supporting the predominant role of bradykinin as
the mediator of swelling in HAE and the absence of substan-
tiating evidence for a kinin derived from C2,32,38 it was of
little surprise that drugs targeting bradykinin generation or
action have shown efficacy in clinical trials for treatment of
acute attacks of angioedema in HAE.40,41
WHAT IS THE MOLECULAR BASIS OF
BRADYKININ-INDUCED SWELLING?
With the demonstration that bradykinin is the mediator
of swelling in HAE, more attention has been paid to the
mechanisms that influence the ability of bradykinin to induce
angioedema. In particular, the catabolism of bradykinin, the
expression of bradykinin receptors, and the signaling events
that result in swelling need to be considered.
Bradykinin is catabolized by a variety of peptidases
(also called kininases). The most important peptidase in the
catabolism of bradykinin is angiotensin converting enzyme
(ACE); other important peptidases involved in the metabo-
lism of bradykinin include aminopeptidase P (APP), car-
boxypeptidase N, neutral endopeptidase, and dipeptidyl pep-
tidase IV.42,43 Decreasing activity of these peptidases (such as
by using an ACE inhibitor) can increase the half-life of
bradykinin and potentially worsen HAE disease severity.
Decreased levels of APP have been detected in patients on
ACE inhibitors who develop angioedema.44 Interestingly,
long-term prophylaxis treatment of HAE with danazol results
in increased APP activity,45 suggesting that long-term pro-
phylaxis therapy with danazol may improve symptoms, in
part, by increasing bradykinin catabolism.
Bradykinin is a pluripotent nanopeptide that mediates a
variety of physiologic and pathologic effects (reviewed in 46).
Binding of bradykinin to the bradykinin B2 receptor on
vascular endothelial cells results in a marked increase in
microvascular permeability. Lung et al47 reported that HAE
clinical severity is influenced by a polymorphism in the
noncoding first exon of the bradykinin B2 receptor that
affects bradykinin B2 receptor expression. Although a sub-
sequent study failed to observe this pattern in a different
cohort,48 other studies have confirmed the role of this polymor-
phism in modulating bradykinin actions.49,50 Additionally, a
recent report suggested that the permeability enhancement in
HAE attacks may be transduced by a combination of bradykinin
B2 receptors and induced bradykinin B1 receptors.51
The mechanism by which bradykinin enhances vascular
permeability is thought to primarily involve its effects on the
phosphorylation of vascular endothelial cell cadherin (VE-
cadherin). VE-cadherin is the key protein involved in the
formation of endothelial tight junctions, which regulate water
movement across the endothelial layer. Bradykinin activates
phospholipase-C, leading to increases in intracellular calcium
and diacylglycerol (DAG), and activating protein kinase C.
Protein kinase C phosphorylates beta-catenin and leads to the
internalization and destruction of the VE-cadherin; it is also
involved in the generation of the vasodilator nitric oxide.52
Activated protein kinase C also phosphorylates myosin light
chain kinase, promoting actin cytoskeleton contraction.
Therefore, bradykinin causes the glue between the cells to
disappear and causing the cells to centripetally contract. The
net effect of this is to increase the gap between vascular
endothelial cells, allowing water to move from the vascular
space into the tissue. Clinically, this is angioedema.
In conclusion, HAE results from mutations in the SER-
PING1 gene, leading to production of a mutant C1 inhibitor
protein that is either not secreted (type I HAE) or dysfunc-
tional (type II HAE). The lack of sufficient functional C1
inhibitor in plasma to adequately inhibit the contact system
proteases plasma kallikrein and coagulation factor XIIa re-
sults in increased generation of bradykinin, which acts on
bradykinin B2 receptors to enhance vascular permeability.
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